Clinical Trials Directory

Trials / Recruiting

RecruitingNCT06855368

Biomarkers for Monitoring Dementia Progression

Brain Connectivity and Complexity Parameters to Monitor Disease Progression in Dementia Patients and Antiinflammatory Nanotherapeutics in a Preclinical Model of Alzheimer's Disease

Status
Recruiting
Phase
Study type
Observational
Enrollment
300 (estimated)
Sponsor
IRCCS San Raffaele Roma · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers

Summary

The variable course of Alzheimer's disease (AD) and the paucity of adequate cures urges to implement new strategies for its early detection and clinical intervention. Studying the etiopathogenesis and pathophysiological mechanisms of AD is a necessary prerequisite for the development of new biomarkers and innovative therapies. Contrarily to anatomical structures, cortical connectivity networks are already deteriorated in early AD and could be a reliable marker of early cognitive decline. Our aim is to characterize the neurophysiological parameters in mild AD, in patients with mild cognitive impairment and in matched healthy subjects to identify discriminating criteria. Concurrently, the study of AD onset and progression in a mouse model, will allow evaluating the causal effect of inflammation on disease progression and to develop a new class of biomimetic anti-inflammatory nanoparticles formulated to have the intrinsic ability to induce brain's activated microglia to an M2 phenotype.

Conditions

Timeline

Start date
2023-05-18
Primary completion
2025-05-17
Completion
2025-12-31
First posted
2025-03-03
Last updated
2025-03-03

Locations

2 sites across 1 country: Italy

Source: ClinicalTrials.gov record NCT06855368. Inclusion in this directory is not an endorsement.

Biomarkers for Monitoring Dementia Progression (NCT06855368) · Clinical Trials Directory